Posters

Bleeding

P101 Asingle centre experience on the safety of newly initiated oral anticoagulation therapy for non-
valvular atrial fibrillation in adult patients.
Helen-Cara Younan, United Kingdom

P103 Bleeding phenotype in cohort of patients with Von Willebrand disease in west Algeria.
Dris Benlaldj, Algeria

P104 Identification of Chinese Hospitalized Patients’ Risk Profile for Venous Thromboembolism (DissolVE 2): Factors Affecting Venous Thromboembolism Risk and Prophylaxis in Hospital Care Setting in China.
Chen Wang, China

P105 Importance of thrombine generation tests in patients in treatment with DOACs
Maria Ida Fernandez Rodriguez, Spain

P106 Hemorrhagic and thrombotic complications in patients with direct action anticoagulants
according to the type of drugs.
Maria Ida Fernandez Rodriguez, Spain

P107 Extended half-life factor VIII: from biology to patients’ management optimization
Andreas Perrier-Cornet\’, France

P108 Development and characterization of neutralizing monoclonal antibodies targeting the direct
oral anticoagulant edoxaban.
Eric Maurer, France

P109 Acquired von Willebrand syndrome associated with cerebral aneurysm.
Dominique Desprez, France

P110 Bariatric surgery in patients with inherited coagulation deficiencies: an experiment in
Strasbourg University Hospital.
Dominique Desprez, France

P111 A retrospective observational study on patients with moderate/severe (M/S) hemophilia A in
France: HEMONIS study - Methodology and Results on the M/S population.
Thierry Lambert, France

P112 Study of Coagulation Factor Inhibitors in Patients with Hemophilia in Kermanshah.
Mehrdad Payandeh, Iran

P113 Surgical experiment on haemophilia B patients treated by eftrenonacog alpha (rFIXFc) in
Strasbourg: about 3 case reports
Dominique Desprez, France

P114 Estimating the long-term cost of bleeding events associated with the use of anticoagulant
therapy in a European setting: a systematic literature review.
Elisabeth Reimer, Denmark

P115 Betrixaban: Impact on routine and specific coagulation assays - A practical laboratory guide.
Romain Siriez, Belgium

P116 Improvement of chromogenic anti-Xa assay to measure betrixaban concentration in plasma.
Romain Siriez, Belgium
P117 Pharmacokinetic parameters, FVIII consumption and cost of 13 patients with severe haemophilia who have switched from conventional therapy to Efmoroctocog alfa: experience of a French haemophilia centre.
Claire Flaujac, France

P118 Standardization and automation of thrombin generation assay: TG on its way to the clinical lab for haemophilia patients.
David Courtois, France

P119 Establishment of a thrombin generation threshold in severe haemophiliac patients under prophylaxis to further determine an added value of this test in the personalized treatment: a pilot study.
Nathaniel Moszynski, Belgium

P120 Primary hemostasis imbalance during ECMO therapy: preliminary study in Rennes hospital.
Fabienne Nedelec, France

P123 Endogenous thrombin potential (ETP) and overall hemostatic potential (OHP) in patients with hemophilia A with inhibitors at baseline and in samples spiked with bypassing agents Roza Chaireti, Sweden

P124 A new rapid, specific and simple ELISA for VWF-Propeptide
Hans-Jürgen Kolde, Germany

P125 Diagnosis strategy of the Von Willebrand disease in the west Algeria: Single center experience.
Driss Benlaldj, Algeria

P126 A retrospective observational study on patients with moderate/severe (M/S) hemophilia A in France: HEMONIS study - Results of the Severe population
Thierry Lambert, France

P127 An alternative approach for improving factor ix results in hemophilia B patients treated with alprolix®
Sophie Voisin, France

P128 effect of cell saver on haemostasis parameters during cardiopulmonary by-pass surgery
Agnès Ribes, France

P129 Which FVIII:C assay for the monitoring of patients with hemophilia undergoing surgery under the cover of FVIII-Fc fusion protein?
Anne Lienhart, France

P130 Gastrointestinal Bleeding and Angiodysplasia in von Willebrand Disease: Results from the secondary interim analysis of the French HRQoL Study: WiSH-QoL.
Annie Borel Derlon, France

P131 Massive Spontaneous Haemothorax in a Hemophilic Child: A rare case report
Peyman Eshghi, Iran

P132 Efficacy of escalating method of prophylactic low dose factor treatment in children with severe hemophilia A & B: Sonographic and clinical scoring outcomes
Peyman Eshghi, Iran

P133 Management of prostate biopsy and prostate cancer therapy in patients with haemophilia: a retrospective French multicentre study
Christine Biron-Andreani, France
Optimisation of the calibration curve for the accurate measurement of low FVIII levels with one-stage FVIII assays
Dorien Van den Bossche, Belgium

Uncommon cause of the prolonged bleeding events – case report
Renata Pizurova, Slovakia

Successful management of delivery in rare bleeding disorder patients: An 11 year experience
Fatemeh Malek, Iran

Emicizumab transforms lifestyle of patients with inhibitor: a qualitative research in haemophilia A
Thierry Lambert, France

Palliative management of a giant iliopsoas haemophilic pseudotumour under emicizumab prophylaxis
Antoine Rauch, France

Does a variation of +/- 2°C around 37°C in the incubation temperature influence the measurement of FVIII inhibitor titres?
Amen Allah Nasr, France

Association of acquired hemophilia A and IgG4-related disease: case report and pathophysiological study
Emmanuelle Jean-Pierre, France

Genetic analysis in Slovak family with inherited factor XIII deficiency
Jana Zolkova, Slovakia

Can von Willebrand antigen level be able to predict the clinical outcome in patients with severe Hemophilia A at the initial presentation?
Selin Aytac, Turkey

Acquired type 3 von Willebrand syndrome associated with splenic marginal zone lymphoma: a case report
Anna Selmeczi, Hungary

Prenatal diagnosis of hemophilia a – five years experience
Nina Ilic, Serbia

A case of severe acquired factor X deficiency: diagnosis approach and clinical management of a rare bleeding disorder
Remy Favre, France

Impact of extended half-life recombinant factor VIII Fc in consumption of FVIII in Haemophilia patients A with prophylaxis regimen
Valerie Chamouard, France

Preliminary study aiming at collecting the opinion of patients and their caregivers about the development of an electronic diary for rare bleeding disorders in France
Lola Seapot-Boucherit, France

Thrombinography and fibrinography in geriatric patients over 80 years with atrial fibrillation receiving rivaroxaban, apixaban, or dabigatran
Geoffrey Foulon, France
Clinical evaluation and implementation of a second generation assay in immuno-turbidimetric method for d-dimer testing in Cameroon
Abene Nnama Louis Hervé, Cameroon

Non-recommended dosing of direct oral anticoagulants in the treatment of acute pulmonary embolism is related to an increased rate of adverse events
Romain Chopard, France

Prescription Patterns of Direct Oral Anticoagulants in Pulmonary Embolism: A prospective multicenter multidisciplinary French registry
Romain Chopard, France

Extended anticoagulation for the secondary prevention of venous thromboembolic events: an updated network meta-analysis
Jean-Christophe Lega, France

Combined thrombophilia: experience in our centre.
Bianca Díaz Roldán, Spain

Role of the thrombophilia study in ischemic cryptogenetic ictus in the young patient: experience in our centre.
Bianca Díaz Roldán, Spain

Changes in renal function in patients with non valvular atrial fibrillation starting an oral anticoagulant
Alberto Maino, Italy

Evaluation of the Cobas t711 coagulation analyzer: a single center experience
Christelle Orlando, Belgium

Lack of standardization of the anti-factor (F)Xa activity and the anti-FXa-correlated a PTT therapeutic ranges used in monitoring unfractionated heparin treatments
Pierre Toulon, France

Monitoring treatments by unfractionated heparin (UFH). Stability of plasma anti-Xa activity for up to 4 hours in citrated tubes
Pierre Toulon, France

The use of the age-adjusted D-dimer threshold to exclude pulmonary embolism
Athanasia Agorasti, Greece

Fibrinolytic portrait for different thrombotic conditions in women
Eugene Roitman, Russia

Significance of the application the therapeutic plasma exchange (TPE) in patients with thrombotic thrombocytopenic purpura (TTP)
Bratislav Stankovic, Serbia

Bone Marrow Necrosis in Patient with Antiphospholipid Syndrome: Case Report and Review of Literature
Nahlah ALGhasham, Saudi Arabia

Direct oral anticoagulants for treatment of cerebral venous sinus thrombosis
Marco Capecchi, Italy

Predictors of venous thromboembolism in patients undergoing neurosurgery for glioma
Marco Capecchi, Italy

High dietary intake of marine n-3 fatty acids is associated with reduced risk of recurrent VTE
Trond Isaksen, Norway
Prognostic factors of catheter-related thrombosis (CRT) are different than prognostic factors of VTE in patients with cancer. Data from the ONCOCIP study.
Laurent Bertoletti, France

Joint effects of atrial fibrillation and prothrombotic genotypes on the risk of ischemic stroke. The Tromsø Study.
Erin Mathiesen Hald, Norway

Joint effects of atrial fibrillation and prothrombotic genotypes on the risk of venous thromboembolism. The Tromsø Study.
Erin Mathiesen Hald, Norway

Slow infusion of reduced dose of alteplase decreases 30-day mortality in patients with intermediate-risk pulmonary embolism.
Slobodan Obradovic, Serbia

Evaluation of human-sourced lipid interferences on three different D-dimer enhanced latex immunoassays.
Frédéric Esteve, France

Health education and clinical-biological monitoring in patients with DOACs and their impact on thrombotic and hemorrhagic complications
Maria Ida Fernandez Rodriguez, Spain

Plasma Fibrinogen Level in Sudanese Patients with Type2 Diabetes Mellitus
Hana Elkhalifa, Sudan

Prognostic Impact of Non-Compliance with Guidelines-Recommended Treatment of Acute Pulmonary Embolism: Results from a Prospective Multicenter Registry
Romain Chopard, France

Thrombotic risk evaluation of factor V Leiden mutation with thrombin generation test: a retrospective study in Rouen University hospital
Paul Billoir, France

After One Month Of Treatment With Apixaban Pulmonary Embolism Patients Have Higher Activity Of Coagulation Factor II, As Compared With Patients Treated With Rivaroxaban And Dabigatran
Boris Dzudovic, Serbia

Regular physical activity and risk of recurrent venous thromboembolism (VTE) and VTE-related mortality
Line Holtet Evensen, Norway

Determination of reference values of factor II and factor X activity levels in our laboratory for the monitoring of vitamin K antagonist therapy
Stéphanie Désage, France

Direct comparisons of brain natriuretic peptide and cardiac troponin I for the prediction of thirty-day all-cause death and pulmonary embolism-cause death in patients with acute pulmonary embolism.
Ljiljana Kos, Bosnia Herzegovina

Identification of Chinese Hospitalized Patients’ Risk Profile for Venous Thromboembolism (DissolVE 1): a Nationwide, Multi-center, Observational study
Li Xiaoying, China
Real life Spanish cohort of direct oral anticoagulants in patients with atrial fibrillation: refase registry
Juan Jose Cerezo, Spain

Miren Gabilondo Jalón, Spain

Myocardial infarction as a trigger of incident venous thromboembolism: Results from a case-crossover study.
Joakim Sejrup, Norway

Joint effects of myocardial infarction and prothrombotic genotypes on the risk of venous thromboembolism: The Tromsø Study
Joakim Sejrup, Norway

Determinants and prognostic impact of diagnosis delay in pulmonary embolism
Celine Goyard, France

Evaluation of haemostasis perturbations in two mice models of Chronic Kidney Disease
Camélia Makhloufi, France

Attenuation of monocytes induced procoagulant activity on CoCr surfaces with thin films of degradable polar/hydrophobic/ionic polyurethanes
Audrey Gossart, France

A new assay to evaluate microvesicle plasmin generation capacity: validation in disease with fibrinolysis imbalance.
Sylvie Cointe, France

A simple, inexpensive and robust assay to measure levels of negatively charged phospholipids – a modified PPL assay.
Cathrine Ramberg, Norway

Coagulation factors FVIII, FXI, and FXII and outcomes after first ischemic stroke in PROSCIS-B
Jessica Rohmann, Germany

Frequency of FV Leiden (R506Q), prothrombin 20210G>A and MTHFR 677C>T variants in a group of pediatric patients with stroke from Serbia
Jelena Vukajlovic, Serbia

Management of high-risk pregnant patients on anticoagulant treatment
Lucia Stanciakova, Slovakia

Inherited and acquired risk factors of thrombosis – a single-centre experience
Lucia Stanciakova, Slovakia

Micro-ribonucleic acid in high-risk pregnancy
Lucia Stanciakova, Slovakia

High-risk pregnant women and genetic changes in the expression of deoxyribonucleic acid
Lucia Stanciakova, Slovakia

Rationale and update of Hokusai post-VTE study: a follow-up study on long-term outcomes of venous thromboembolism in patients treated with heparin/edoxaban vs heparin/warfarin
Ingrid Bistervels, The Netherlands

Influence of arterial hypertension on different venous thrombosis types
Biljana Vuckovic, Serbia
P202 Thrombosis of v.portae and v.lienalis in pregnant woman with thrombophilia – Case study
Ivana Pesic Stevanovic, Serbia

P203 International Pediatric Thrombosis Network: advancing the field of pediatric thrombosis
Heleen van Ommen, The Netherlands

P204 Coagulopathy and Pregnancy - Overview of Case
Emilija Kochovska, Macedonia

P205 Thrombotic events associated with central venous catheter in patients admitted at a Pediatric
Intensive Care Unit of Sao Joao University Hospital
Maria Ramalho, Portugal

P206 Acquired Factor XI Inhibitor interfering with the essays of intrinsic pathway factors: a case
report.
Kahina Ghemmour Guenounou, Algeria

P207 Protein C deficiency - a case report
Tatjana Timova, Macedonia

P208 Evaluation of thrombotic risk in antithrombin deficiency variant by thrombin generation assay
Paul Billoir, France

P209 Interest of IgG and IgM anti-prothrombin autoantibodies in the exploration of anti-phospholipid
syndrome: a 5 years retrospective study
Daniel Bertin, France

P210 Potential value of magnetic resonance direct thrombus imaging in preventing over diagnosis
by compression ultrasound in patients with suspected ipsilateral recurrent deep venous
thrombosis
Gargi Gautam, Sweden

P211 Molecular and laboratory characteristics of recessive von Willebrand Disease 2N anno 2018
Jan Jacques Michiels, The Netherlands

P212 Evaluation of classical and novel von Willebrand factor assays in von Willebrand disease
patients Jan Jacques Michiels, The Netherlands

P213 Monitoring argatroban with rotational thromboelastometry: an emergency alternative to
activated partial thromboplastin time?
Corentin Bassi, France

P214 Joint effects of D-dimer and prothrombotic genotypes on the future risk of incident venous
thromboembolism
Ellen-Sofie Hansen, Norway

P215 Does in-vitro addition of activated charcoal allow lupus anticoagulant testing with dRVVT in
plasma of patients treated with DOAC?: the CAVIAR study
Virginie Siguret, France

P216 Interactions between argatroban and vitamin K antagonists on clotting tests (APT and aPTT)
and interest of argatroban measuring during perioperative management: case report.
Sara Boukhlal, France

P217 Comparison between the standard thrombin generation method and the automated thrombin
generation technique
Marc Arus, Spain

P218 ABO blood group and factor VIII levels in thrombophilic families
Maria Ordoñez Garcia, Spain
Macrophages stimulated in vitro with LPS and ATP produce large IL-18-positive microparticles which can be detected in patients with systemic-onset juvenile idiopathic arthritis
Richard Bachelier, France

Removal of DOACs from plasma: performance comparison and pre-analytical considerations of three different devices
Celine Bouvy, Belgium

The presence of anti-ADAMTS13 autoantibodies does not change ADAMTS13 antigen levels measured by an in house developed ADAMTS13 antigen
Elisa Charlotte Dekimpe, Belgium

A optimized method to measure tissue factor activity on microvesicles.
Loris Valler, France

The effect of lower-leg injury and knee arthroscopy on coagulation factor levels
Carolina Touw, The Netherlands

Genomic Variations in the Fibrinolytic cascade and their role in Venous Thrombosis
Aniket Prabhudesai, India

Clot waveform analysis: Determination of optimal wavelength to assess the fibrin coagulation process
Jonathan Evrard, Belgium

Clot waveform analysis for measuring and quantifying fibrin clot formation
Jonathan Evrard, Belgium

The relationship between absorbance and fibrinogen in the clot waveform analysis
Jonathan Evrard, Belgium

Clot waveform analysis: Do the reagents of intrinsic, extrinsic and common coagulation pathway interfere with baseline absorbance
Jonathan Evrard, Belgium

Sara Horta, Belgium

Caveats in detection of tissue factor
Bjarne Østerud, Norway

GWAS identifies new risk variants in ADAMTS13/STKLD1 locus for deep venous thrombosis
Jana-Ch. Hegenbarth, Germany

Bring of the high multiplex Real-time chain polymerase reaction (PCR)
Soraya Hadjali-Saichi, Algeria

Immunoglobulins of healthy donors – a source of anti-idiotypic antibodies against anti-ADAMTS13 autoantibodies in immune-mediated thrombotic thrombocytopenic purpura (iTTP) patients?
Kadri Kangro, Belgium

From autoantibodies to therapeutics: en route to novel treatment for immune TTP
Bogac Ercig, The Netherlands
The balance between fibrin clot formation and fibrinolysis may predict cardiovascular events in patients with stable coronary artery disease
Søs Neergaard-Petersen, Denmark

Annual cost of clotting factors in patients with severe (SEV) hemophilia A (HA) in France - an ancillary analysis of hemonis study
Benoit Polack, France

A rare case of antiphospholipid syndrome-associated middle cerebral artery stenosis in a young patient presenting with moya-moya pattern: a therapeutic challenge for the internist
Maria Mylona, Greece

State of the knowledge on the set up of medical compression in patients at high risk of thrombosis
Valérie Chamouard, France

Mice Lacking the Novel Thrombosis Susceptibility Gene S1c44a2 Have Normal Hemostasis but an Aberrant Response to Vascular Injury
Julia Tilburg, The Netherlands

Mean platelet volume predicts the complications of arteriovenous fistula in hemodialyzed patients
Guillaume Lano, France

Role of factor VIII in clot growth and sensitivity to reversible factor Xa inhibitors
Cornelis Kluft, The Netherlands

Rheumatoid arthritis closes the gap in hemostatic balance between pre- and postmenopausal women
Aleksandra Vranic, Serbia

Thrombin generation is increased in patients with chronic urticaria that associate angioedema
Álvaro Fernández-Pardo, Spain

Utility of the Thrombin Generation Test in various clinical phenotypes to predict thrombotic recurrences in cancer patients without anticoagulant treatment
Álvaro Fernández-Pardo, Spain

Assessment of hypercoagulable state in patients with preeclampsia using global haemostatic assays
Violeta Dopsaj, Serbia

Point-of-care-INR testing: Challenges
Jurgita Janukonyte, Denmark

The significance of the fibrinolysis state in cancer patients receiving chemotherapy
Vladimir Sukhanov, Russia

Congenital dysfibrinogenemia – a single centre experience
Vera Geierova, Czech Republic

The shortened activation peptide of Pseudonaja textilis venom FX abrogates activation by the intrinsic tenase complex
Geraldine Poenou, The Netherlands

Measuring Anti-Factor Xa Peak Levels in Pregnant Women Receiving Therapeutic Enoxaparin Dose: A Prospective Observational Study
Fahad Al-Eidan, Saudi Arabia
P253  Two mutations in the FGB gene in patients with a quantitative fibrinogen disorder with bleeding and thrombotic phenotype
Tomas Simurda, Slovakia

P254  Risk factors, thromboprophylaxis and occurrence of thrombotic events in multiple myeloma patients attending a university hospital.
Sofia Teixeira, Portugal

P255  Does addition of three SNPs to the genetic investigation of thrombophilia give better risk prediction in a cohort that was clinically tested after VTE or family history of VTE?
Maria Farm, Sweden

P256  Clinical factors associated with PE in patients initially subjected to diagnostic cardiac work up: A Swedish cross-sectional study from over ninety thousand emergency department visits
Philip Smith, Sweden

P257  Association of an Afibrinogenemia and a FV Leiden in two patients within the same family.
Soraya Hadjali-Saichi, Algeria

P258  The incidence of coagulopathy after adverse reactions to platelet transfusions in pediatric hematooncology patients
Olivera Serbic, Serbia

P259  Overall hemostatic potential and thrombin generation in patients with atrial fibrilation receiving rivaroxaban
Anica Petkovic, Serbia

P260  Advanced proteomic approach to identify a specific protein plasma profile associated to venous thromboembolism
Álvaro Fernández-Pardo, Spain

P261  Haemostatic disturbances in children with acute leukemia at presentation and during induction therapy-single center experience
Milena Jovic, Serbia

P262  Management of intraoperative anticoagulation for cardiopulmonary bypass heart transplantation in a patient with acute heparin-induced thrombocytopenia undergoing heart transplantation.
Marie Toussaint, France

P263  Anticoagulant Protein Level Differences Between Young and Elderly Patients with Myocardial Infarction
Antonijevic Nebojsa, Serbia

P264  Platelet aggregation induced by serine proteinase isolated from Vipera lebetina snake venom: involvement of purinergic signaling pathway
Amel Kadi-Saci, Algeria

P265  Does the response to antiplatelet therapy influence the appearance of thromboembolic events in patients with carotid stenosis and eversion endarterectomy-pilot study
Tina Novakovic, Serbia

P266  Flavonoid metabolites with antiplatelet effects
Lenka Applova, Czech Republic

P267  Biological Evaluation of the Therapeutic Effectiveness of Platelet Antiaggregant in Patients with Coronary Pathology
Hacene Brouk, Algeria
P268 Fluoxetine amplifies ticagrelor mediated protection during myocardial reperfusion injury
Maximilian Mauler, Germany

P269 Comparison of manual and automated platelet count in patients with low platelets
Dragana Milić, Serbia

P270 Evaluation of heparin-induced multiple electrode aggregometry method for the diagnosis of
heparin-induced thrombocytopenia using 5B9 as a reference hit IGG antibody
Claire Pouplard, France

P271 Assessment of light transmission aggregometry on the routine coagulation analyzer Siemens
CS-2500 using CE-marked agonists from Hyphen Biomed
Chloé James, France

P273 A novel rapid method of platelets and red blood cells permeabilization and staining for flow
cytometry analysis.
Sixtine Faure, France

P274 Standardisation of platelet sialylation quantification by flow cytometry and reference values in
healthy subjects
Dominique Lasne, France

P275 Specific features of fluorophore sequestering in platelets allow more precise measurement of
calcium concentration in cytosol
Alexey Martyanov, Russia

P276 Functional HIT testing based on flow cytometry-our experiences
Ingrid Skornova, Slovakia

P277 Contribution of the MAIPA Test in the Biological Exploration of ITP
Hacene Brouk, Algeria

P278 Long-term safety and efficacy of eltrombopag in pediatric chronic immune thrombocytopenia
(cITP): An extension study of Russian patients previously enrolled in PETIT2
Elena Donyush, Russia

P279 Autologous Platelet-Released Growth Factor and sexual dysfunction amendment: A Case
series of successful improvement sexual dysfunction after pelvic irradiation
Saeed Mohammadi, Iran

P280 Optimised tools for evaluation of platelet function measured by impedance aggregometry
Anna Schultz-Lebahn, Denmark

P281 Endothelial activation in acquired thrombotic thrombocytopenic purpura: mechanisms and
correlation with disease severity
Edwige Tellier, France

P282 Effect of Direct Oral Anticoagulants on platelet reactivity
Georges Jourdi, France

P283 Coagulopathy associated with Isolated Traumatic Brain Injury
Anastasia Baranich, Russia

P284 Platelet function in preterm neonates
Alexander Grevsen, Denmark

P285 No integrin deactivation assessed by fibrinogen binding to platelets was observed during
reversible platelet aggregation induced by ADP
Aleksandra Filkova, Russia
Modulation of the platelet count by Romiplostim and inhibitors of LIM kinase in genetically-engineered von Willebrand disease type 2B mice: in vivo evaluation of haemostatic efficiency. Mathilde Cheptou, France

Assessment of Platelet Aggregation with Automated Method Among Tunisian Healthy Blood Donors
Hadef Skouri, Tunisia

A novel GATA 1 mutation identified within one French family with thrombocytopenia and microcytosis
Sophie Bayart, France

Stormorken-Sjaastad-Langslet syndrome: a new family.
Sophie Bayart, France

Imaging P2Y12-inhibited and non-inhibited platelets in the building thrombus under flow in vitro
Tomas Lindahl, Sweden

Adipocyte influences megakaryopoiesis: a link with obesity
Sonia Severin, France

MicroRNA and hyperaggregability of thrombocytes in sticky platelet syndrome- our first experiences
Lubica Vadelova, Slovakia

Validation of a rapid von Willebrand factor propepide assay
Muriel Meiring, South Africa

Effect of plasma components on Staphylococcus aureus adhesion to tissues used for the right ventricular outflow tract (RVOT) revalvulation
Bartosz Ditkowski, Belgium